Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

MYOBLOC

Aliases
botulinum toxin type B, Phase 2; High Dose MYOBLOC, Phase 2; Low Dose MYOBLOC, Phase 3; MYOBLOC, rimabotulinumtoxinB
Name
Myobloc
INN Name
rimabotulinumtoxinB
FDA Approved
Yes

3 clinical trials

1 organization

7 indications

1 document

Indication
Sialorrhea
Indication
Spasticity
Indication
Stroke
Indication
Multiple Sclerosis
Indication
Traumatic Brain Injury
Indication
Spinal Cord Injury
Indication
Cerebral Palsy
Clinical trial
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® for the Treatment of Chronic Sialorrhea in Pediatric Subjects
Status: Not yet recruiting, Estimated PCD: 2023-12-31
Clinical trial
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in Treatment of Adult Upper Limb Spasticity and Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Clinical trial
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Status: Active (not recruiting), Estimated PCD: 2023-04-01
Document
DailyMed Label: Myobloc
Organization
Solstice Neurosciences, LLC